Skip to main content
Lung Cancer
ADJUVANT Study: Quality of Life with Adjuvant Gefitinib versus Vinorelbine plus Cisplatin in Patients with EGFR-Mutant NSCLC
Read More
Lung Cancer
Ensartinib in Crizotinib-Resistant, ALK-Positive NSCLC
Read More
Lung Cancer
Afatinib + Cetuximab versus Afatinib Alone for the First-Line Treatment of EGFR-Mutant NSCLC (SWOG S1403)
Read More
Lung Cancer
Afatinib in Asian and Non-Asian Patients with EGFR Mutation–Positive NSCLC Harboring Uncommon Mutations
Read More
Lung Cancer
NEJ009 Study: Gefitinib Alone versus Gefitinib + Chemotherapy for EGFR-Mutant NSCLC
Read More
Lung Cancer
GEOMETRY Mono-1 Study: Capmatinib in MET Exon 14–Mutated or MET-Amplified NSCLC
Read More
Lung Cancer
IMpower150 Study: Atezolizumab in Combination with Bevacizumab and Chemotherapy in EGFR-Mutated NSCLC
Read More
Lung Cancer
Tarloxotinib in Patients with Advanced NSCLC Harboring an EGFR Exon 20 Insertion or HER2-Activating Mutation
Read More
Lung Cancer
Capmatinib + Nazartinib for EGFR-Mutant NSCLC
Read More
Lung Cancer
NSCLC Year in Review Introduction
Read More
Page 102 of 199
Results 1011 - 1020 of 1986